Kymera Therapeutics (KYMR) Net Income towards Common Stockholders (2019 - 2026)

Kymera Therapeutics (KYMR) has reported Net Income towards Common Stockholders for 8 consecutive years, with -$69.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Net Income towards Common Stockholders fell 5.57% year-over-year to -$69.2 million; the TTM figure through Mar 2026 stood at -$315.0 million (down 30.77% YoY), while the FY2025 annual figure was -$311.4 million, down 39.08% from the prior year.
• Net Income towards Common Stockholders rose to -$69.2 million in Q1 2026 per KYMR's latest filing, from -$87.0 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at -$14.4 million in Q4 2023 and bottomed at -$168.5 million in Q1 2022.
• Historically, Net Income towards Common Stockholders has averaged -$61.1 million across 5 years, with a median of -$52.9 million in 2023.
• On a YoY basis, Net Income towards Common Stockholders climbed as much as 84.09% in 2022 and fell as far as 1188.61% in 2022.
• Kymera Therapeutics' Net Income towards Common Stockholders stood at -$34.9 million in 2022, then soared by 58.79% to -$14.4 million in 2023, then tumbled by 392.43% to -$70.8 million in 2024, then fell by 22.94% to -$87.0 million in 2025, then climbed by 20.4% to -$69.2 million in 2026.
• Business Quant data shows KYMR's Net Income towards Common Stockholders at -$69.2 million in Q1 2026, -$87.0 million in Q4 2025, and -$82.2 million in Q3 2025.